Back
Ovid Therapeutics 10K Form
Buy
63
OVID
Ovid Therapeutics
Last Price:
1.19
Seasonality Move:
-0.69%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-11-03 | 10Q | OVID/Ovid Therapeutics Quarterly |
| 2023-08-04 | 10Q | OVID/Ovid Therapeutics Quarterly |
| 2023-05-05 | 10Q | OVID/Ovid Therapeutics Quarterly |
| 2022-11-08 | 10Q | OVID/Ovid Therapeutics Quarterly |
| 2022-08-09 | 10Q | OVID/Ovid Therapeutics Quarterly |
| 2022-05-10 | 10Q | OVID/Ovid Therapeutics Quarterly |
Receive OVID News And Ratings
See the #1 stock for the next 7 days that we like better than OVID
OVID Financial Statistics
Sales & Book Value
| Annual Sales: | $391.7K |
|---|---|
| Cash Flow: | $-14.41M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $1.25 |
| Price / Book: | 0.99 |
Profitability
| EPS (TTM): | -0.43000 |
|---|---|
| Net Income (TTM): | $-29.75M |
| Gross Margin: | -- |
| Return on Equity: | -31.85% |
| Return on Assets: | -22.71% |
Ovid Therapeutics Earnings Forecast
Key Ovid Therapeutics Financial Ratios
- The Research & Development expenses have been 7,298.41% of Revenue.
- The Net Earning history of OVID is -13,362.00% of Total Revenues.
- Per Share Earnings over the last 9 years have been positive in 5 years.
Ovid Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | OVID |
| CUSIP: | 690469 |
| Website: | ovidrx.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 5.73 |
| Quick Ratio: | 5.45 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
OVID Technical Analysis vs Fundamental Analysis
Buy
63
Ovid Therapeutics (OVID)
is a Buy
Is Ovid Therapeutics a Buy or a Sell?
-
Ovid Therapeutics stock is rated a Buy
The current Ovid Therapeutics [OVID] share price is $1.23. The Score for OVID is 63, which is 26% above its historic median score of 50, and infers lower risk than normal.